Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 2.28
0.441 %
$ 19.9 M
Market Cap
-2.71
P/E
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease.[ Read More ]
The intrinsic value of one BFRG stock under the base case scenario is HIDDEN Compared to the current market price of 2.28 USD, Bullfrog AI Holdings, Inc. Common Stock is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart BFRG
FINANCIALS
65 K
REVENUE
-5.37 M
OPERATING INCOME
-5.36 M
NET INCOME
-6 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
8.57 M
FINANCING CASH FLOW
0
REVENUE
-1.82 M
OPERATING INCOME
-1.76 M
NET INCOME
-1.21 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
-169 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Bullfrog AI Holdings, Inc. Common Stock
| Current Assets | 2.77 M |
| Cash & Short-Term Investments | 2.62 M |
| Receivables | 0 |
| Other Current Assets | 146 K |
| Non-Current Assets | 5.97 K |
| Long-Term Investments | 0 |
| PP&E | 5.97 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 184 K |
| Accounts Payable | 104 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 80.7 K |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Bullfrog AI Holdings, Inc. Common Stock
| Revenue | 65 K |
| Cost Of Revenue | 5.2 K |
| Gross Profit | 59.8 K |
| Operating Expenses | 5.43 M |
| Operating Income | -5.37 M |
| Other Expenses | -11.7 K |
| Net Income | -5.36 M |
RATIOS
92.00%
GROSS MARGIN
-8257.73%
OPERATING MARGIN
-8239.80%
NET MARGIN
-206.61%
ROE
-192.89%
ROA
-207.06%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bullfrog AI Holdings, Inc. Common Stock
| Net Income | -5.36 M |
| Depreciation & Amortization | 1.72 K |
| Capital Expenditures | -1 |
| Stock-Based Compensation | 682 K |
| Change in Working Capital | -1.44 M |
| Others | -888 K |
| Free Cash Flow | -6 M |
Wall Street Analysts Price Targets
Bullfrog AI Holdings, Inc. Common Stock
BFRG has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Bullfrog AI Holdings, Inc. Common Stock
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
324 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
9 months ago
Jan 22, 2024
|
Sell 188 K USD
|
Singh Vininder
Chief Executive Officer |
- 25000
|
7.5 USD |
|
10 months ago
Jan 16, 2024
|
Sell 21.7 K USD
|
Singh Vininder
Chief Executive Officer |
- 8516
|
2.553 USD |
|
10 months ago
Jan 17, 2024
|
Sell 15.4 K USD
|
Singh Vininder
Chief Executive Officer |
- 4848
|
3.1849 USD |
|
10 months ago
Jan 10, 2024
|
Sell 13.2 K USD
|
Singh Vininder
Chief Executive Officer |
- 4780
|
2.7523 USD |
|
10 months ago
Jan 11, 2024
|
Sell 14.6 K USD
|
Singh Vininder
Chief Executive Officer |
- 5660
|
2.5818 USD |
|
10 months ago
Jan 12, 2024
|
Sell 3.87 K USD
|
Singh Vininder
Chief Executive Officer |
- 1515
|
2.5564 USD |
|
10 months ago
Jan 05, 2024
|
Sell 7.66 K USD
|
Singh Vininder
Chief Executive Officer |
- 2644
|
2.8979 USD |
|
10 months ago
Jan 08, 2024
|
Sell 14.9 K USD
|
Singh Vininder
Chief Executive Officer |
- 5184
|
2.8791 USD |
|
10 months ago
Jan 09, 2024
|
Sell 8.86 K USD
|
Singh Vininder
Chief Executive Officer |
- 3144
|
2.8179 USD |
|
10 months ago
Jan 02, 2024
|
Sell 14 K USD
|
Singh Vininder
Chief Executive Officer |
- 4464
|
3.1429 USD |
|
10 months ago
Jan 03, 2024
|
Sell 12.4 K USD
|
Singh Vininder
Chief Executive Officer |
- 5676
|
2.1834 USD |
|
10 months ago
Jan 04, 2024
|
Sell 10 K USD
|
Singh Vininder
Chief Executive Officer |
- 3569
|
2.8023 USD |
|
1 year ago
Sep 05, 2023
|
Sell 147 K USD
|
Singh Vininder
Chief Executive Officer |
- 50000
|
2.9497 USD |
|
1 year ago
Jun 14, 2023
|
Bought 20.2 K USD
|
Enright William
Director |
+ 5000
|
4.05 USD |
7. News
BullFrog AI's VP Artificial Intelligence to Present at Google's Cancer AI Symposium
GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google's inaugural Cancer AI Symposium on October 30, 2024, at the Boston Center for the Arts.
globenewswire.com
- 3 weeks ago
WallachBeth Capital Announces Closing of Bullfrog AI Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has closed its previously announced definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00.
prnewswire.com
- 3 weeks ago
Bullfrog AI Announces Closing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
GAITHERSBURG, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has closed its previously announced definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00. The warrants will have an exercise price of $2.00 per share, are initially exercisable on the date that is six months from the date of issuance and will expire five years from such initial exercise date.
globenewswire.com
- 3 weeks ago
WallachBeth Capital Announce Pricing of Bullfrog AI's Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
JERSEY CITY, N.J. , Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00.
prnewswire.com
- 4 weeks ago
Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
GAITHERSBURG, Md., Oct. 18, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00. The warrants will have an exercise price of $2.00 per share, are initially exercisable on the date that is six months from the date of issuance and will expire five years from such initial exercise date.
globenewswire.com
- 4 weeks ago
BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientific research and technology-driven drug discovery.
globenewswire.com
- 1 month ago
BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114
GAITHERSBURG, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the publication of new research in the peer-reviewed journal Cell Reports supporting the potential of BullFrog AI's drug candidate, BF-114 (SPTBN1 siRNA), in treating a range of liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and hepatocellular carcinoma (HCC). The research was generated in a study led by Lopa Mishra, MD, professor of medicine, Merinoff Endowed Chair and co-director of the Institute for Bioelectronic Medicine at Feinstein Institutes for Medical Research at Northwell Health, Cold Spring Harbor Laboratory.
globenewswire.com
- 1 month ago
Top 4 Health Care Stocks That May Keep You Up At Night
As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
benzinga.com
- 1 month ago
BullFrog AI to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a leader in AI-driven drug discovery, announced today that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held in New York City.
globenewswire.com
- 2 months ago
BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets
Discussions underway for drug target discovery deals with potential pharma partners Discussions underway for drug target discovery deals with potential pharma partners
globenewswire.com
- 3 months ago
Join BullFrog AI's Exclusive Live Investor Webinar and Q&A Session on June 12
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on June 12, 2024, at 4:15 p.m. ET.
globenewswire.com
- 5 months ago
BullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorders
GAITHERSBURG, Md., May 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug discovery company using artificial intelligence (AI) and machine learning to enable the successful discovery and development of pharmaceuticals and biologics, today announced significant advancements in its collaboration with the Lieber Institute for Brain Development (LIBD), including the identification of potential drug targets for multiple neuropsychiatric conditions.
globenewswire.com
- 6 months ago
8. Profile Summary
Bullfrog AI Holdings, Inc. Common Stock BFRG
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 19.9 M
Dividend Yield
0.00%
Description
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
Contact
325 Ellington Blvd., Gaithersburg, MD, 20878
https://www.bullfrogai.com
IPO Date
Feb. 13, 2023
Employees
4
Officers
Dr. Cetin Savkli Ph.D.
Chief AI Advisor & Member of Advisory Board
Hon. Thomas W. Chittenden X, DPHIL, Ph.D.
Chief Scientific Officer
Dr. David P. Recker FACP, FACR, M.D.
Chief Medical Officer
Mr. Vininder Singh
Founder, Chairman & Chief Executive Officer
Mr. Dane R. Saglio
Chief Financial Officer
Mr. J. T. Koffenberger
Chief Information Officer